Rupesh Dash
Scientist-D
Department of Biotechnology
Institute of Life Sciences, Nalco Square
India
Biography
Career Scientist D: Institute of Life Sciences (2015 onwards) Ramalingaswami Fellow: Institute of Life Sciences, (2012-2015) Post-Doctoral Fellow: VCU Medical Center, Richmond, VA Research Fellow: Institute of Molecular and Cell Biology, Singapore Ph.D. Department Biotechnology, IIT Kharagpur, India Fellowships and Awards Ramalingaswami Fellow DST-INSPIRE Faculty Department of Defense Prostate Cancer Training Award Senior Research Fellowship, Council of scientific and industrial research, New Delhi Junior Research Fellowship, Indian council of agricultural research, New Delhi. Recognitions Recognized as Ph.D. Guide of : Manipal University, KIIT
Research Interest
Gene Therapy for Cancer
Publications
-
Dash R, Azab B, Quinn BA, Shen X, Wang XY, Das SK, Rahmani M, Wei J, Hedvat M, Dent P, Dmitriev IP. Apogossypol derivative BI-97C1 (Sabutoclax) targeting Mcl-1 sensitizes prostate cancer cells to mda-7/IL-24–mediated toxicity. Proceedings of the National Academy of Sciences. 2011 May 24;108(21):8785-90.
-
Dash R, Bhoopathi P, Das SK, Sarkar S, Emdad L, Dasgupta S, Sarkar D, Fisher PB. Novel mechanism of MDA-7/IL-24 cancer-specific apoptosis through SARI induction. Cancer research. 2014 Jan 15;74(2):563-74.
-
Samal SK, Routray S, Veeramachaneni GK, Dash R, Botlagunta M. Ketorolac salt is a newly discovered DDX3 inhibitor to treat oral cancer. Scientific reports. 2015;5.
-
Maji S, Samal SK, Pattanaik L, Panda S, Quinn BA, Das SK, Sarkar D, Pellecchia M, Fisher PB, Dash R. Mcl-1 is an important therapeutic target for oral squamous cell carcinomas. Oncotarget. 2015 Jun 30;6(18):16623.
